AbCellera Biologics prices offering of common shares and pre-funded warrants at undisclosed terms

Filed August 11, 2026 · ~2 min read

Key Changes

• high

  Offering size, price per share, and total proceeds are not disclosed in this 424B5 filing; all dollar fields in the pricing table are blank placeholders. The company's shares traded at $9.32 on August 10, 2026.

  The Offering verify on EDGAR →
• high

  Net proceeds will fund research, development and clinical advancement of the internal pipeline including lead program ABCL635, plus working capital. The company retains broad discretion to redirect proceeds.

  Use of Proceeds verify on EDGAR →
• medium

  The offering includes pre-funded warrants with a nominal $0.00001 exercise price, economically equivalent to common shares. The company will receive no meaningful additional proceeds when warrants are exercised.

  Dilution verify on EDGAR →